Adverse drug reactions pose a significant healthcare challenge, with hypersensitivity reactions being particularly unpredictable and often severe, sometimes resulting in unfavorable outcomes. These reactions underscore the importance of enhancing drug safety through advances in pharmacogenomics. It is critical to deepen research into the mechanisms that cause these exaggerated responses, as well as to improve management strategies and identify biomarkers associated with hypersensitivity. By accurately predicting such reactions, we can develop safer treatment protocols for various diseases, ultimately improving the quality of life for patient populations around the world.
Further research into pharmacogenomic biomarkers, including those affecting drug metabolism and transport, is essential. Prospective studies should aim to refine genetic guidelines for prescribing medications and assess the cost-effectiveness of implementing pharmacogenomics in managing hypersensitivity reactions. While some countries have successfully integrated these practices into clinical settings, making prevention a tangible achievement, the scope of biomarker identification needs to be broadened. This expansion should cover unexplored populations and investigate additional drugs known for causing hypersensitivity reactions, as well as other immunological and metabolic factors involved in these adverse responses.
This Research Topic is open for Original Articles, Systematic Reviews, Methods, Reviews, Mini Reviews, Policy and Practice Reviews, Hypotheses and Theories, Perspectives, Clinical Trials, Case Reports, Community Case Studies, Data Reports, Policy Briefs, Brief Research Reports, and Opinions, addressing:
- The physiopathology of hypersensitivity reactions.
- In-vitro, in-vivo, and in-silico studies of pharmacogenomic biomarkers related to hypersensitivity reactions (HLA alleles, related to immunologic system and/or the pharmacodynamics and pharmacokinetics of drugs, etc).
- The implementation of pharmacogenomic biomarkers in hypersensitivity reactions.
- Pharmacoeconomic studies related to genetic tests and the prevention of hypersensitivity reactions.
- Molecular methods for the assessment of HLA alleles relevant in the pharmacogenomics of hypersensitivity reactions.
- Bioinformatics studies including the evaluation of pharmacogenomic biomarkers related to hypersensitivity reactions.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section of Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or insufficient experimental validation, will not be included in this Research Topic.
Keywords: pharmacogenetics, pharmacogenomics, HLA, allergy, DILI, drugs, hypersensitivity, DRESS, SJS
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
